69 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
. Travere also completed regulatory engagement on focal segmental glomerulosclerosis (FSGS) in which the FDA communicated that the Phase 3 DUPLEX study
425
w5dcqc um
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.1
pb254mgjve4s
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
2le6vz0 s9d
20 Oct 20
Results of Operations and Financial Condition
10:52am
8-K
EX-2.1
ctz44qnm01ix9bok1x
13 Oct 20
Entry into a Material Definitive Agreement
8:44am
8-K
EX-10.1
dyemh8
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-10.2
rxuzqnqiw3swk7b
10 Sep 20
Entry into a Material Definitive Agreement
4:43pm
SC TO-T
EX-99
6sf0 j15ar4xqx
31 Aug 20
Third party tender offer statement
8:46am
SC TO-C
EX-2.1
h6gxsc 45c
10 Aug 20
Information about tender offer
9:50pm
8-K
EX-2.1
9r7i5clx2zk439 7vi
10 Aug 20
Tender and Support Agreement
9:48pm